Results 171 to 180 of about 4,640 (210)
Some of the next articles are maybe not open access.
CNSC-51. SELINEXOR FOR THE TREATMENT OF GLIOMA: A RETROSPECTIVE CASE SERIES
Neuro-OncologyHigh grade gliomas are aggressive primary brain tumors. Following progression, treatment options are limited and prognosis is poor. The need for novel agents is unmet. Selinexor is an inhibitor of exportin-1 (XPO-1) currently approved for treatment
Edward Lee +8 more
semanticscholar +1 more source
Selinexor dose optimization: A retrospective analysis.
JCO Oncology Practice296 Background: Several oral oncolytics are approved at doses that require early and frequent intervention to manage associated toxicities. This retrospective analysis investigated efficacy and safety outcomes of patients initiated on lower doses (≤ 80 mg) of selinexor compared to those who ...
Rachel Hauf +8 more
openaire +1 more source
Identification of XPO1 interactors and modulation by selinexor in diffuse large B cell lymphoma
BloodDiffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL). Relapsed/refractory (R/R) patients commonly have poor outcomes, highlighting the need for novel treatment regimens.
Kyla Trkulja +12 more
semanticscholar +1 more source
Drug resistance biomarker ABCC4 of selinexor and immune feature in multiple myeloma
International Immunopharmacology, 2022Da-Wei Wang, Yang Liang, Yu-Jun Dai
exaly